Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis.
Tate M JohnsonHarlan R SaylesJoshua F BakerMichael D GeorgePunyasha RoulCheng ZhengBrian SauerKatherine P LiaoDaniel R AndersonTed R MikulsBryant R EnglandPublished in: Annals of the rheumatic diseases (2021)
MTX use in RA was associated with a reduced risk of CVD events, particularly HF-related hospitalisations. These associations were not mediated through reductions in RA disease activity, suggesting alternative MTX-related mechanisms may modify CVD risk in this population.